Area of research
Pulmonary and Respiratory Medicine · Molecular Biology · organoid drug screen
Research interest
creates a powerful synergy: Dr. Hammers brings clinical trial design, biomarker development, and immunotherapy expertise with emphasis on genitourinary cancers and early-phase clinical trials, while Dr. Minna provides deep translational research experience, preclinical model development, and mechanisms for moving basic science discoveries toward clinical application. Dr. Minna's leadership focuses on helping basic science investigators develop roadmaps to translate findings to the clinic, facilitating inter-programmatic translational interactions across SCCC programs, and directing the weekly Hamon Center/ET Program seminar series—the main forum for bidirectional laboratory-clinic collaboration attended by all SCCC Research Programs. Together, the ET Co-Leaders oversee faculty recruitment
Association of Vaping-Related Events with Relative Harm Perceptions of E-Cigarettes.
Cancer cachexia in STK11/LKB1-mutated non-small cell lung cancer is dependent on tumor-secreted GDF15.
ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin.
Understanding immune checkpoint inhibitor efficacy through spatial decoding of the lung cancer tumor immune microenvironment
High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Lipoylation inhibition enhances radiation control of lung cancer by suppressing homologous recombination DNA damage repair
Lipoylation inhibition enhances radiation control of lung cancer by suppressing homologous recombination DNA damage repair.
High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non-Small Cell Lung Cancer in Patients.
The Current State of Tumor Microenvironment-Specific Therapies for Non-Small Cell Lung Cancer.
The Integrated Stress Response Pathway Coordinates Translational Control of Multiple Immune Checkpoints in Lung Cancer.
High <i>KYNU</i> Expression Is Associated with Poor Prognosis, <i>KEAP1</i>/<i>STK11</i> Mutations, and Immunosuppressive Metabolism in Patient-Derived but Not Murine Lung Adenocarcinomas.
TMPRSS11B promotes an acidified microenvironment and immune suppression in squamous lung cancer.
HIF-2-Dependent Regulation of PTHrP and Paraneoplastic Hypercalcemia in Aggressive Clear-Cell Renal Cell Carcinoma.
KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma.
The Lung Cancer Autochthonous Model Gene Expression Database Enables Cross-Study Comparisons of the Transcriptomic Landscapes Across Mouse Models.
The Lung Cancer Autochthonous Model Gene Expression Database Enables Cross-Study Comparisons of the Transcriptomic Landscapes Across Mouse Models
TMPRSS11B promotes an acidified microenvironment and immune suppression in squamous lung cancer
High KYNU Expression Is Associated with Poor Prognosis, KEAP1/STK11 Mutations, and Immunosuppressive Metabolism in Patient-Derived but Not Murine Lung Adenocarcinomas
Kinase Suppressor of Ras 2 Promotes Self-Renewal and Clonogenicity of Small-Cell Lung Carcinoma
Supplementary Figure 6 from The Integrated Stress Response Pathway Coordinates Translational Control of Multiple Immune Checkpoints in Lung Cancer
Figure 6 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Table S1 from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Supplementary Table 2 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Table 3 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Table 5 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Figure S4 from A Comparative Study of Neuroendocrine Heterogeneity in Small Cell Lung Cancer and Neuroblastoma
Supplementary Figure 3 from High Glucose Contribution to the TCA Cycle Is a Feature of Aggressive Non–Small Cell Lung Cancer in Patients
Supplementary Table 3 from The Integrated Stress Response Pathway Coordinates Translational Control of Multiple Immune Checkpoints in Lung Cancer
Supplementary Figure S1 from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma
Supplementary Figure S3 from KSR2 Promotes Self-Renewal and Clonogenicity of Small Cell Lung Carcinoma